# SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.

Source: https://onco.cc/trials/nct06835179/  
OnCo record `nct06835179` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of cAPOX (capecitabine, oxaliplatin) and bevacizumab (glioblastoma use) in colorectal cancer, run by The First Affiliated Hospital with Nanjing Medical University, not yet recruiting.

## Summary

SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer. is a phase 2, interventional study registered as NCT06835179 by The First Affiliated Hospital with Nanjing Medical University, with a registry enrolment figure of 28 participants, started 2025-02 and due to reach its primary completion in 2027-02. Interventions recorded: SBRT; PD-1 Inhibitors; CapeOX + bevacizumab. Conditions listed: Unresectable Metastatic Colorectal Cancer; Microsatellite Stable (MSS) Colorectal Cancer (CRC); RAS-mutant Colorectal Cancer. Primary outcome: Objective response rate (ORR rate). Colorectal eligibility wording from the registry: "* Histologically confirmed colorectal adenocarcinoma". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06835179
- Phase: 2
- Setting: Evaluation of the Efficacy and Safety of SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor in RAS-Mutant, MSS-Type, and Unresectable Metastatic Colorectal Cancer: a Single-center, Single-arm, Open-label Clinical Trail.
- Sponsor: The First Affiliated Hospital with Nanjing Medical University
- Enrolled: 28

## Sources

- ClinicalTrials.gov NCT06835179: https://clinicaltrials.gov/study/NCT06835179

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06835179.json